Increased sensitivity of a metastatic model of prostate cancer to a novel tetravalent platinum analog

Prostate

Volumn 62, Issue 1, 2005, Pages 91-100

  Mujoo, Kalpana ^a   Watanabe, Masayuki ^a,b   Khokhar, Abdul R ^a   Siddik, Zahid H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Cell cycle; p53; Platinum complexes; Prostate; Signal transduction

Indexed keywords

(DIAMINOCYCLOHEXANE)(DIACETATO)(DICHLORO)PLATINUM; ANDROGEN; ANTINEOPLASTIC AGENT; CISPLATIN DERIVATIVE; PLATINUM DERIVATIVE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DNA ADDUCT; DNA DAMAGE; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SCREENING; DRUG SENSITIVITY; DRUG TOLERANCE; DRUG UPTAKE; GENOTYPE; HUMAN; HUMAN CELL; MALE; MITOSIS INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WILD TYPE;

ANDROGENS; ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; CYCLIN D1; DNA ADDUCTS; GENES, P53; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 10144251765     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20114     Document Type: Article

References (41)

1. Parker S, Tong T, Bolden S, Wingo P. Cancer statistics CA. Cancer J Clin 1997;47:5-27.
2. Lara PN, Jr, Kung H-J, Gumerlock PH, Meyers FJ. Molecular biology of prostate carcinogenesis. Crit Rev Oncol/Hematol 1999;32:197-208.
3. Weinberg RA. Tumor suppressor genes. Science 1991;254:1138-1146.
4. Lane DP. p53: Guardian of genome. Nature 1992;358:15-16.
5. Downing SR, Russell PJ, Jackson P. Alterations of p53 are common in early stage prostate cancer. Can J Urol 2003;10:1924-1933.
6. Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, Von Eschenbach AC, Logothetis CJ. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol 1999;161:304-308.
7. Marcelli M, Cunningham GR, Walkup M, He Z, Sturgis L, Kagan C, Mannucci R, Nicoletti I, Teng B, Denner L. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP. Overexpression of caspase 7 as a new gene therapy strategy for prostate cancer. Cancer Res 1999;59:382-390.
8. Rossof AH, Talley RW, Stephens R, Thigpen T, Samson MK, Groppe C Jr., Eyre HJ, Fisher R. Phase II evaluation of CDDP in advanced malignancies of the genitourinary and gynecologic organs. Cancer Treat Rep 1979;63:1557-1564.
9. Huan SD, Stewart DJ, Aitken SE, Segal R, Yan JC. Combination of epirubicin and cisplatin in harmone-refractory metastatic prostate cancer. Am J Clin Oncol 1999;22:471.
10. Siddik ZH, Hagopian GS, Thai G, Tomisaki S, Toyomasu T, Khokhar AR. Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV)to circumvent cisplatin resistance. J Inorg Biochem 1999;77:65-70.
11. Siddik ZH, Mims B, Lozano G, Thai G. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res 1998;58:698-703.
12. Hagopian GS, Mills GB, Khokhar AR, Bast RC, Siddik ZH. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: Modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)- platinum(IV). Clin Cancer Res 1999;5:655-663.
13. Vollano JF, Al-Baker S, Dabrowiak JC, Schurig JE. Comparative antitumor studies on platinum(II) and platinum(IV) complexes containing 1,2-diaminocyclohexane. J Med Chem 1987;30:716-719.
14. Siddik ZH, Boxall FE, Harrap KR. Flameless atomic absorption spectrophotometric determination of platinum in tissues solubilized in hyamine hydroxide. Anal Biochem 1987;163:21-26.
15. Pettaway CA, Pathak S, Green G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 1996;2:1627-1637.
16. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ, Jr, Kohn KW. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997;57:4285-4300.
17. DeWeese TL, Shipman JM, Dillehay LE, Nelson WG. Sensitivity of human prostatic carcinoma cell lines to low dose radiation exposure. J Urol 1998;159:591-598.
18. Appella E, Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 2001;268:2764-2772.
19. Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, Paul JD, Hbaiu A, Goode RG, Sandusky GE, Vessella RL, Neubauer BL. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000;275:24500-24505.
20. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, Kreisberg JI. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002;8:1168-1171.
21. Pfeil K, Eder IE, Putz T, Ramoner R, Culig Z, Ueberall F, Bartsch G, Klocker H. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. The Prostate 2003;9999:1-10.
22. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, Isaacs WB, Bova GS. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998;58:204-209.
23. Ferrante K, Winograd B, Canetta R. Promising new developments in cancer chemotherapy. Cancer Chemother Pharmacol 1999;43:61-68.
24. Kelland LR. An update on satraplatin: The first orally available platinum anticancer drug. Expert Opin Investig Drugs 2000;9:1373-1382.
25. Aprikian AG, Sarkis AS, Fair WR, Zhang ZF, Fuks Z, Cordon-Cardo C. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 1994;151:1276-1280.
26. Borsellino N, Belldegrun A, Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995;55:4633-4639.
27. Yee CS, Kamradt JM, Nielsen LC, Panvinchian R, Pienta KJ. Carboplatin-induced cell death in model prostate cancer systems. Anticancer Res 1998;18(6A):4475-4482.
28. Ahmed S, Hershberger PA, Zuhowski EG, Egorin MJ, Trump DL, Johnson CS, Oxaliplatin activity in prostate cancer. AACR 2002; Abstract #312.
29. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999;59:4291-4296.
30. Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, Yung WKA, Steck PA. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 1999;59:2551-2556.
31. Lin H-K, Yeh S, Kang H-Y, Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci 2001;98:7200-7205.
32. Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 2002;277:5484-5489.
33. Vousden KH. Activation of the p53 tumor suppressor protein. Biochim Biophys Acta 2002;1602:47-59.
34. Kapoor M, Lozano G. Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc Natl Acad Sci USA 1998;95:2834-2837.
35. Kapoor M, Hamm R, Yan W, Taya Y, Lozano G. Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation. Oncogene 2000;19:358-364.
36. Reed JC. Regulation of apoptosis by Bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 1995;7:541-546.
37. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21 WAF1/CIP1. Nature 1996;381:713-716.
38. Fan S, Chang JK, Smith ML, Duba D, Fornace AJ, Jr, O'Connor PM. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene 1997;14:2127-2136.
39. Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW, Fornace AJ, Jr, O'Connor PM. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995;55:1649-1654.
40. WAF1/CIP1 cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. Cancer Lett 2000;161:17-26.
41. Tsao YP, Huang SJ, Chang JL, Hsieh JT, Pong RC, Chen SL. Adenovirus-mediated p21 WAF1/CIP1 ((WAF1/SDII/CIP1)) gene transfer induces apoptosis of human cervical cancer cell lines. J Virol 1999;73:4983-4990.